There is one clinical trial.
Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.
Description: Improvement of pulmonary function. Arterial oxygen tension PaO2 (in mmHg)/fractional inspired oxygen FiO2 (expressed as a fraction, not a percentage), most conveniently the P/F ratio. The normal P/F ratio is ~ 400-500 mmHg (~55-65 kPa). P/F ratio <300mmHg - sign of Acute Respiratory Distress Syndrome (ARDS)
Measure: Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio. Time: up to 28 daysDescription: Length of Hospital Stay
Measure: Changes in length of hospital stay Time: up to 28 daysDescription: Marker for efficacy of treatment
Measure: Changes in mortality rate Time: up to 28 daysDescription: Infection biomarker. Serum CRP levels can be used for early diagnosis of pneumonia, patients with severe pneumonia had high CRP levels.
Measure: Changes of С-reactive protein (CRP, mg/L) Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8Description: CT assessment of pulmonary lesions and lung tissue changes
Measure: Evaluation of Pneumonia Improvement Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8Description: Indirect response to lung function
Measure: Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.) Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8Description: Degree of infection
Measure: Peripheral blood count recovery time Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8